Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, on the basis of the crystal structure of K-Ras, 21 analogues (TKR01-TKR21) containing urea or thiourea were rationally designed, which can effectively inhibit the lung cancer cell A549 growth.
|
31851852 |
2020 |
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Despite substantial progress in lung cancer immunotherapy, the overall response rate in KRAS-mutant lung adenocarcinoma (ADC) patients remains low.
|
31744829 |
2020 |
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
KRAS is the most commonly mutated oncogene in human cancers, such as pancreatic cancers, colon cancers, and lung cancers.
|
31456522 |
2019 |
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Combined mTOR, IGF1R, and MEK inhibition inhibits the principal signaling pathways required for the survival of KRAS-mutant cells and produces marked tumor regression in three different KRAS-driven lung cancer mouse models.
|
31534020 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers.
|
30626603 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
|
31484165 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
RNAi induced knockdown using siRNAs against mutant KRAS alleles offers a promising tool for selective therapeutic silencing in KRAS-mutant lung cancers.
|
31289919 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The impact of EGFR and KRAS mutations in Brazilian lung cancer remains poorly explored.
|
30824880 |
2019 |
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results indicate that REG4 plays an important role in KRAS-driven lung cancer pathogenesis and is a novel biomarker of lung adenocarcinoma subtype.
|
31428934 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We also observed co-expression of genes in this Chk1 chromatin pathway in TNBC and KRAS mutant lung cancers.
|
30607635 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12).
|
31668570 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results pinpoint mTOR as a mechanism of resistance to chemotherapy in KRAS-mutant lung cancer and validate a rational and readily translatable strategy that combines mTOR inhibitors with standard chemotherapy to treat KRAS-mutant adenocarcinoma, the most common and deadliest lung cancer subset.
|
30171261 |
2019 |
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we show that long-term supplementation with the antioxidants N-acetylcysteine and vitamin E promotes KRAS-driven lung cancer metastasis.
|
31257027 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings demonstrate that the miR-148a-3p may play a significant role in NSCLC including the kind of lung cancer with K-Ras gene mutation, and it exerted the tumor inhibitor function by targeting SOS2.
|
30536836 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A total of 1271 small molecules were screened in KRAS-mutant and wild-type lung cancer cell lines.
|
30862488 |
2019 |
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Since mutated KRAS has been implicated in the development of various cancers including lung cancer, we tested a mutant-allele specific siRNA against KRAS<sup>G12S</sup>, in A549 cells.
|
30771430 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations may act as a resistance mechanism to MET inhibition in MET dependent lung cancer.
|
31200822 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Except for the detection of ERBB2 amplification and KRAS mutation in two patients, no other classic lung cancer driver mutations were detected.
|
31659278 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer cell lines with KRAS mutation were relatively more sensitive to KRA-533 than cell lines without KRAS mutation.
|
30971271 |
2019 |
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Gene set enrichment analysis of transcriptomic data from lung cancers with <i>MET</i>ex14 revealed preferential activation of the KRAS pathway.
|
30352902 |
2019 |
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken together, these results provide a novel mechanistic understanding of how the IKKβ pathway affects human lung tumorigenesis, indicating that IKKβ promotes KRAS-induced angiogenesis both by cancer cell-intrinsic and cancer cell-independent mechanisms, which strongly suggests IKKβ inhibition as a promising antiangiogenic approach to be explored for KRAS-induced lung cancer therapy.
|
30885340 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele.
|
30366101 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS is the most commonly mutated oncogene in human cancer, with particularly high mutation frequencies in pancreatic cancers, colorectal cancers, and lung cancers [Ostrem, J. M., and Shokat, K. M. (2016) Nat.Rev.Drug Discovery 15, 771-785].
|
31042025 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To begin with, we developed a pipeline to utilize a set of computational tools in order to obtain the most deleterious nsSNPs (Q22K, Q61P, and Q61R) associated with lung cancer in the human KRAS gene.
|
31117243 |
2019 |
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Using the LA2 K-Ras G12D-induced model for lung cancer, we show that Kif2b expression reduces the number of chromosome segregation defects but does not change the incidence of lung tumor lesions.
|
31179849 |
2019 |